Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYB | P10242 | 13/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8813293 | 0.85 | MYB (0.55) | MYBMAPTHTTSMN1; SMN2ACHE | |
| SCHEMBL8541677 | 0.83 | MYB (0.66) | MYBMAPTHTTSMN1; SMN2ACHE | |
| SCHEMBL8543444 | 0.81 | MYB (0.70) | MYBMAPTHTTSMN1; SMN2ACHE | |
| SCHEMBL8542128 | 0.80 | MYB (1.00) | MYBMAPTALDH1A1KDM4EGAA | |
| SCHEMBL8543812 | 0.78 | MEN1 (0.67) | MYBMAPTACHEALDH1A1LMNA | |
| SCHEMBL8813284 | 0.73 | MYB (0.54) | MYBMAPTHTTSMN1; SMN2ACHE | |
| SCHEMBL9342930 | 0.72 | MYB (0.57) | MYBMAPTHTTSMN1; SMN2ACHE | |
| SCHEMBL8810542 | 0.71 | MYB (0.74) | MYBMAPTALDH1A1KDM4EGAA | |
| SCHEMBL10275379 | 0.71 | MYB (0.74) | MYBMAPTALDH1A1KDM4EGAA | |
| SCHEMBL10275382 | 0.71 | MYB (0.74) | MYBMAPTALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0537949-B1 | Antiproliferative derivatives of 4H-naphtho 1,2-b pyran | LILLY CO ELI (GB) | 1998-07-01 | — | — | EP | disclosed |
| EP-0618206-B1 | Pharmaceutical compounds | LILLY INDUSTRIES LTD (GB) | 1997-09-17 | — | — | EP | disclosed |
| US-5576325-A | TREATMENT OF IMMUNE DISEASES, RESTENOSIS, ENZYME INHIBITORS AND ANTISPASMODIC AGENTS | LILLY INDUSTRIES LIMITED (GB) | 1996-11-19 | — | — | US | disclosed |
| US-5574034-A | TREATMENT OF IMMUNE DISEASES AND EXCESS CELL PROLIFERATION, ENZYME INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-11-12 | — | — | US | disclosed |
| US-5571818-A | FOR TREATING IMMUNE DISEASES OR A DISEASE IN WHICH EXCESS CELL PROLIFERATION OR ENZYME RELEASE OCCUR | ELI LILLY AND COMPANY (US) | 1996-11-05 | — | — | US | disclosed |
| US-5514699-A | Pharmaceutical compounds | LILLY INDUSTRIES LIMITED (GB) | 1996-05-07 | — | — | US | disclosed |
| EP-0618206-A1 | Pharmaceutical compounds | LILLY INDUSTRIES LIMITED (GB) | 1994-10-05 | — | — | EP | disclosed |
| US-5284868-A | Naphthopyran derivatives; for autoimmune diseases, cancer | ELI LILLY AND COMPANY (US) | 1994-02-08 | — | — | US | disclosed |
| US-5281619-A | Administering naphtho(1,2-B)pyran derivatives | ELI LILLY AND COMPANY (US) | 1994-01-25 | — | — | US | disclosed |
| EP-0537949-A1 | Antiproliferative derivatives of 4H-naphtho 1,2-b pyran | LILLY INDUSTRIES LIMITED (GB) | 1993-04-21 | — | — | EP | disclosed |